The most commonly reported side effects of lefamulin include diarrhoea, vomiting, and product use in unapproved indication, based on 19 FDA adverse event reports from 2020 to 2025. 5.3% of reports found the drug to be ineffective.
Percentages show how often each reaction appears relative to total reports for lefamulin.
These are voluntary reports and do not establish that lefamulin caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside lefamulin. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
26.3% of lefamulin adverse event reports involve female patients and 36.8% involve male patients. The largest age group is adult at 67%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking lefamulin when the adverse event was reported.
Lefamulin is sold under the brand name Xenleta.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.